EGFR mutationradiotherapyTKILung cancer is the leading cause of cancer-related death globally and poses a considerable threat to public health. Asia has the highest prevalence of epidermal growth factor receptor (EGFR) mutations in patients with non-small cell lung cancer (NSCLC). Despite the ...
Gefitinib is a medication used to treat certain cancers, specifically non-small cell lung cancer (NSCLC). By targeting the epidermal growth factor receptor (EGFR) and inhibiting its tyrosine kinase activity, gefitinib helps restore balance in cell proliferation. It is particularly effective in NSCLC ...
The first of these inhibitors targeted a protein called the "epidermal growth factor receptor," or EGFR. Researchers found that many lung cancers had surfaces littered with the excess product of EGFR proteins, so they developed an EGFR inhibitor to suppress these growth factors. It worked, slowing...
However, objective response rate (ORR) or progression-free survival (PFS) is limited compared with other molecular-targeted therapies, such as epidermal growth factor receptor (EGFR) inhibitors [13]. Therefore, efforts are being made to develop improved RAS drugs. This review focuses on the ...
insights into the current role of thalidomide, especially by comparing thalidomide-containing regimens with protocols based on newer-generation IMiDs and by investigating thalidomide’s association with novel therapies (e.g., antibody-drug conjugates, bispecific antibodies, and chimeric antigen receptor T ...
Targeted anticancer drugs block the cell signaling system that targets cancer cells, and many new drugs are being developed, including EGFR (epidermal growth factor receptor) and ALK (anaplastic lymphoma kinase). "Targeted anticancer drugs are mainly oral drugs, and they are very effective when admi...
Tagrisso (osimertinib) is a kinase inhibitor for treating a lung cancer called non-small cell lung cancer (NSCLC) when the cancer is advanced or metastasized (stage 4). It is used in patients with a T790M mutation in the epidermal growth factor receptor (EGFR):1,2 as first-line treatment...
33(19):2197–204) have performed a randomised, double-blind, multicentre, placebo-controlled, phase III study of first-line bevacizumab plus carboplatin/paclitaxel (B+CP) vs placebo plus carboplatin/paclitaxel (Pl+CP) in China where the epidermal growth factor receptor (EGFR) prevalence is 30%...
It’s important to note thatnot all cancersare caused by gene mutations. But, one example of a gene mutation’s link to cancer is theEGFR, or epidermal growth factor receptor, gene. EGFR mutations are often connected with non-small cell lung cancer (NSCLC). These are mutations that only ...
Saltz LB, Rubin M, Hochster H, et al.:Cetuximab (IMCC225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that express epidermal growth factor receptor(EGFR) [abstract].Proceedings of the American Society of Clinical Oncology 2001.Alexandria, VA: American Soc...